-
Je něco špatně v tomto záznamu ?
Cholesterol metabolites modulate ionotropic P2X4 and P2X7 receptor current in microglia cells
M. Barraco, E. Kudova, C. Bucolo, L. Ciranna, MA. Sortino, M. Chisari
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- buněčné linie MeSH
- mikroglie * metabolismus MeSH
- pregnanolon * metabolismus MeSH
- purinergní receptory P2X4 * metabolismus MeSH
- testosteron * metabolismus MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
The central nervous system is a well-known steroidogenic tissue producing, among others, cholesterol metabolites such as neuroactive steroids, oxysterols and steroid hormones. It is well known that these endogenous molecules affect several receptor classes, including ionotropic GABAergic and NMDA glutamatergic receptors in neurons. It has been shown that also ionotropic purinergic (P2X) receptors are cholesterol metabolites' targets. Among P2X receptors, purinergic P2X4 and P2X7 receptors are expressed in microglia, the innate immune cells involved in the brain inflammatory response. In this study, we explore the ionotropic purinergic receptors modulation by cholesterol metabolites in microglia. Patch-clamp experiments were performed in BV2 cells, a murine microglia cell line, to evaluate effects of cholesterol metabolites using micro- and nanomolar concentrations. About P2X4 receptor, we found that testosterone butyrate (20 μM and 200 nM) and allopregnanolone (10 μM and 100 nM) both potentiated its current, while neither 25-hydroxycholesterol (10 μM and 100 nM) nor 17β-estradiol (1 μM) showed any effects. On the other hand, P2X7 receptor current was potentiated by allopregnanolone (10 μM) and 25-hydroxycholesterol (10 μM and 100 nM). Taken together, our data show that modulation of either P2X4 and P2X7 current is affected differently by cholesterol metabolites, suggesting a structure-activity relationship among these players. Identifying the possible link between purinergic transmission, microglia and cholesterol metabolites will allow to define new targets for drug development to treat neuroinflammation.
Dept of Biomedical and Biotechnological Sciences Physiology University of Catania Catania Italy
Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009489
- 003
- CZ-PrNML
- 005
- 20250429134749.0
- 007
- ta
- 008
- 250415e20250102enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.neuropharm.2024.110294 $2 doi
- 035 __
- $a (PubMed)39755203
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Barraco, Michele $u Dept. of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- 245 10
- $a Cholesterol metabolites modulate ionotropic P2X4 and P2X7 receptor current in microglia cells / $c M. Barraco, E. Kudova, C. Bucolo, L. Ciranna, MA. Sortino, M. Chisari
- 520 9_
- $a The central nervous system is a well-known steroidogenic tissue producing, among others, cholesterol metabolites such as neuroactive steroids, oxysterols and steroid hormones. It is well known that these endogenous molecules affect several receptor classes, including ionotropic GABAergic and NMDA glutamatergic receptors in neurons. It has been shown that also ionotropic purinergic (P2X) receptors are cholesterol metabolites' targets. Among P2X receptors, purinergic P2X4 and P2X7 receptors are expressed in microglia, the innate immune cells involved in the brain inflammatory response. In this study, we explore the ionotropic purinergic receptors modulation by cholesterol metabolites in microglia. Patch-clamp experiments were performed in BV2 cells, a murine microglia cell line, to evaluate effects of cholesterol metabolites using micro- and nanomolar concentrations. About P2X4 receptor, we found that testosterone butyrate (20 μM and 200 nM) and allopregnanolone (10 μM and 100 nM) both potentiated its current, while neither 25-hydroxycholesterol (10 μM and 100 nM) nor 17β-estradiol (1 μM) showed any effects. On the other hand, P2X7 receptor current was potentiated by allopregnanolone (10 μM) and 25-hydroxycholesterol (10 μM and 100 nM). Taken together, our data show that modulation of either P2X4 and P2X7 current is affected differently by cholesterol metabolites, suggesting a structure-activity relationship among these players. Identifying the possible link between purinergic transmission, microglia and cholesterol metabolites will allow to define new targets for drug development to treat neuroinflammation.
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a mikroglie $x metabolismus $7 D017628
- 650 12
- $a testosteron $x metabolismus $7 D013739
- 650 12
- $a pregnanolon $x metabolismus $7 D011280
- 650 12
- $a purinergní receptory P2X4 $x metabolismus $7 D058848
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kudova, Eva $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Bucolo, Claudio $u Dept. of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- 700 1_
- $a Ciranna, Lucia $u Dept. of Biomedical and Biotechnological Sciences, Physiology, University of Catania, Catania, Italy
- 700 1_
- $a Sortino, Maria Angela $u Dept. of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy
- 700 1_
- $a Chisari, Mariangela $u Dept. of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy. Electronic address: chisarim@unict.it
- 773 0_
- $w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 266 (20250102), s. 110294
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39755203 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134745 $b ABA008
- 999 __
- $a ok $b bmc $g 2311086 $s 1246570
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 266 $c - $d 110294 $e 20250102 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
- LZP __
- $a Pubmed-20250415